Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

A Physiologically Based Pharmacokinetic Model of Rifampin in Mice

(2013) Michael A. Lyons et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Preliminary Pharmacokinetic Study of Repeated Doses of Rifampin and Rifapentine in Guinea Pigs

(2013) Noton K. Dutta et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Consequences of Noncompliance for Therapy Efficacy and Emergence of Resistance in Murine Tuberculosis Caused by the Beijing Genotype of Mycobacterium tuberculosis

(2012) Jurriaan E. M. de Steenwinkel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis

(2012) Ian M. Rosenthal et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of Escalating Daily Doses of the Antituberculosis Drug Rifapentine in Healthy Volunteers

(2012) K E Dooley et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Importance of Confirming Data on theIn VivoEfficacy of Novel Antibacterial Drug Regimens against Various Strains of Mycobacterium tuberculosis

(2011) Mary A. De Groote et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

(2011) J. van Ingen et al.   CLINICAL INFECTIOUS DISEASES

The complexity of the adherence-response relationship in tuberculosis treatment: why are we still in the dark and how can we get out?

(2011) Jossy van den Boogaard et al.   TROPICAL MEDICINE & INTERNATIONAL HEALTH

Drugs in Development for Tuberculosis

(2010) Ann M. Ginsberg   DRUGS

Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis

(2010) J. E. M. de Steenwinkel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Mycobacterium tuberculosisBeijing Genotype Is an Independent Risk Factor for Tuberculosis Treatment Failure in Indonesia

(2010) Ida Parwati et al.   JOURNAL OF INFECTIOUS DISEASES

Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains

(2010) Ida Parwati et al.   LANCET INFECTIOUS DISEASES

Population Modeling and Monte Carlo Simulation Study of the Pharmacokinetics and Antituberculosis Pharmacodynamics of Rifampin in Lungs

(2009) S. Goutelle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development

(2008) J. van den Boogaard et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY